LL37 Peptide for Sale here for the amazing price of $95.00.
LL-37 is a research peptide that has antimicrobial activity against multiple human pathogens. Antimicrobial peptides (AMPs) have the potential to serve as an alternative to antibiotics. It’s simple, AMPs kill the microbial pathogens or the bugs that can occur in the body. But, without causing any tissue damage or resistance.
What does LL-37 stand for?
LL-37 is a 37 amino acid cationic peptide.
What does LL-37 peptide do?
An ideal antimicrobial would kill the pathogen without destroying the host tissue. In addition, AMPs tend to be very active against drug-resistant organisms. In these studies, we will continue to pursue work on AMPs. We have already investigated LL-37, and characterized the mechanism of action, and determined the minimum inhibitory concentration against pathogens, and developed resistance to the peptides.
Where is LL-37 found?
LL-37 also has been shown to have the ability to enhance the activity of a variety of antimicrobial agents including vancomycin, daptomycin, and polymyxins. Our focus is to determine whether these peptides are effective in the treatment of pneumonia and invasive infection.
Where is LL-37 found?
To date, we have determined that the peptides have activity against a broad spectrum of pathogens. This activity varies among different pathogens with some pathogens showing high levels of sensitivity and others displaying relative resistance.
Preliminary studies have shown that some pathogens are killed by the peptides at extremely high concentrations. In addition, we have shown that the peptides enhance the activity of daptomycin against S. aureus.
LL-37 peptide benefits
LL-37 has the potential to be a broad spectrum, synergistic, and/or additive therapy for multiple pathogen infections, including community-acquired pneumonia. The peptides also may have significant potential for combination therapy with the newer antimicrobial agents. To that end, we have performed preliminary tests of the synergy of the peptides with the newer antimicrobial agents.
LL-37 peptide dosage
In this regard, preliminary data show that there is synergy between CAP18 and daptomycin against methicillin-resistant S. aureus. We will pursue these studies with a special focus on synergy with vancomycin and daptomycin against vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA).
What do Cathelicidins do?
In order to fully investigate these studies, we will need to use both standardized assays and a well-characterized panel of clinical isolates. To that end, we will obtain vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) strains from the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) database. In vitro assays and microdilution, broth assays will be performed to measure the synergy of the peptides and antibiotics.
Synergy will be expressed as fractional inhibitory concentration (FIC) using Etest and micro broth dilution methods. Results from the in vitro studies will be correlated to results from the in vivo studies.